GeoVax is a biotechnology company specializing in the creation, development, and commercialization of human vaccines to combat HIV/AIDS. Designed for predominant HIV virus subtypes in the developed world, our most advanced vaccine candidate is designed for use in uninfected people to protect them from AIDS should they be exposed to the HIV-1 virus.
Type
Public
HQ
Smyrna, US
Founded
2001
Size (employees)
5 (est)
Website
geovax.com
GeoVax was founded in 2001 and is headquartered in Smyrna, US
Report incorrect company information

Key People/Management at GeoVax

Robert T. McNally

Robert T. McNally

President & CEO
Mark W. Reynolds

Mark W. Reynolds

CFO
Harriet L. Robinson

Harriet L. Robinson

CSO

GeoVax Office Locations

GeoVax has an office in Smyrna
Smyrna, US (HQ)
1900 Lake Park Dr SE
Show all (1)
Report incorrect company information

GeoVax Financials and Metrics

GeoVax Financials

USD

Net income (Q1, 2018)

(621.8 k)

EBIT (Q1, 2018)

(622.9 k)

Market capitalization (31-Oct-2017)

3.4 m

Closing share price (31-Oct-2017)

0

Cash (31-Mar-2018)

571.2 k

EV

2.8 m
GeoVax's current market capitalization is $3.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

1.8 m1.8 m1.4 m2.1 m1.2 m

R&D expense

2.9 m1.8 m1.7 m2 m2 m

Operating expense total

4.7 m3.6 m3.1 m4.1 m3.2 m

EBIT

(2.3 m)(2.7 m)(2.7 m)(3.3 m)(2.2 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

General and administrative expense

344.9 k411.8 k401.4 k364.9 k335.9 k906.5 k344.8 k220.7 k292.7 k357.2 k

R&D expense

516.2 k425.5 k403.6 k384.7 k378.5 k438 k397.6 k683.9 k551.8 k487 k

Operating expense total

861.1 k837.3 k805.1 k749.5 k714.5 k1.3 m742.4 k904.6 k844.5 k844.2 k

EBIT

(680.6 k)(515.2 k)(701.6 k)(678.1 k)(621.3 k)(1.3 m)(576.1 k)(464.5 k)(548.7 k)(622.9 k)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

2.5 m1.1 m1.1 m454 k312.7 k

Inventories

43.6 k44.5 k56.6 k62.3 k

Current Assets

2.7 m1.2 m1.2 m544.4 k448.1 k

PP&E

120.2 k96.7 k83.6 k54.8 k31.2 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Cash

1.4 m862.2 k3.1 m2.5 m1.8 m669.5 k215.1 k511.1 k166.7 k571.2 k

Current Assets

1.4 m926.4 k3.2 m2.6 m1.9 m709 k258.8 k602.2 k240.4 k802.3 k

PP&E

103.6 k113.2 k105.3 k98.1 k90.8 k76.4 k69.2 k62 k52.3 k26.2 k

Total Assets

1.5 m1.1 m3.4 m2.7 m2 m796.5 k339.1 k675.2 k303.7 k839.5 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(2.3 m)(2.7 m)(2.7 m)(3.3 m)(2.2 m)

Depreciation and Amortization

78.9 k69 k28.9 k28.8 k28 k

Inventories

(1.3 k)(934 )(12.1 k)(5.6 k)

Accounts Payable

(14.7 k)(125.3 k)(60 k)242.9 k441.4 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(679.5 k)(514.5 k)(700.5 k)(676.2 k)(619.9 k)(1.3 m)(575.8 k)(464.2 k)(548.3 k)(621.8 k)

Depreciation and Amortization

5 k

Accounts Payable

115.4 k82.2 k45.9 k111 k42.5 k102.7 k39.1 k33.5 k150.9 k107.1 k

Cash From Operating Activities

(381.6 k)
USDY, 2018

EV/EBIT

-4.6 x

EV/CFO

-7.4 x

Financial Leverage

-6.5 x
Show all financial metrics
Report incorrect company information

GeoVax Online and Social Media Presence

Embed Graph
Report incorrect company information